Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04522830 · ClinicalTrials.gov registry record · Phase 2
A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19
A Phase 2 study, sponsored by Beech Tree Labs.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT04522830 is a Phase 2 study that has completed, run by Beech Tree Labs. The registered enrollment target is 28 participants.
The verdict
NCT04522830, a Phase 2 study, has completed, sponsored by Beech Tree Labs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.
Interventions
- DRUG Placebo
- DRUG BTL-TML-COVID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2021-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04522830
The ClinicalTrials.gov registry entry for NCT04522830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beech Tree Labs, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04522830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04522830 about?
NCT04522830 is a clinical study titled "A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19". Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.
What is the current status of trial NCT04522830?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2020-07-30. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT04522830?
The interventions under investigation include: Placebo (DRUG), BTL-TML-COVID (DRUG).
Who is sponsoring clinical trial NCT04522830?
This trial is sponsored by Beech Tree Labs, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.